Thompson Tamar 4

What Happened Tamar Thompson, a director of Avidity Biosciences, disposed of a total of 74,215 shares and derivative securities on 2026-02-27 pursuant to the Agreement and Plan of Merger with Novartis. The filings show a disposition of 6,692 shares of common stock (including shares issuable upon settlement of previously reported restricted stock units) and four derivative dispositions totaling 67,523 option/derivative units. The merger consideration was $72.00 per share, so the surrendered equity equals roughly $5.34 million at $72/share; note that option-related proceeds were paid as the cash spread (merger consideration minus each option’s exercise price), not a straight $72 per option share.

Key Details

• Transaction date: 2026-02-27; Form 4 filed the same day (timely).
• Reported dispositions: 6,692 common shares; derivative/option-related dispositions of 10,034; 13,489; 22,000; and 22,000 (total derivative = 67,523). Total = 74,215.
• Price reported on Form 4: N/A. Merger consideration per footnote: $72.00 per share. Option consideration: cash payment equal to ($72.00 − exercise price) per option (per footnote).
• Shares owned after the transactions: not provided in the data you shared.
• Footnotes: F1 — common shares (including RSUs) were disposed pursuant to the Merger Agreement; F2 — options were cashed out under the Merger Agreement for the excess of $72 over exercise price.
• Filing timeliness: filed same day as the reported transactions; not a late filing.

Context These dispositions were merger-related (shares and option-equivalents surrendered to the issuer under the Merger Agreement with Novartis), not open-market sales. For the derivative entries, this was a cash-out of options (the holder received the spread between $72 and the option exercise price), rather than a market sale of exercised shares. Merger-driven cash-outs are routine in deal closings and do not necessarily signal the insider’s ongoing sentiment beyond the contract terms.